VBL Therapeutics Inc., of Tel Aviv, Israel, said it was awarded a nondilutive grant exceeding ILS10 million (US$2.9 million) by the Israel Innovation Authority to support continued development of lead candidate VB-111, a targeted CD95/TNF receptor modulator gene therapy.